Evidence map›Paper›PMID 40297460›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Investigating Primary Care Indications to Improve the Quality of Electronic Health Record Data in Target Trial Emulation for Dementia.

Max Sunog, Colin Magdamo, Marie-Laure Charpignon, Mark Albers

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Max SunogMassachusetts General Hospital, US.
Colin MagdamoHarvard Medical School, US.
Marie-Laure CharpignonInstitute for Data, Systems, and Society, Massachusetts Institute of Technology & Computational Health Informatics Program, Boston Children's Hospital & Harvard Medical School, US.
Mark AlbersMassachusetts General Hospital & Harvard Medical School, US.ORCID 0000-0001-7855-3455

Funding

Harnessing Diverse Bioinformatic Approaches To Repurpose Drugs For Alzheimers Disease And Related DementiasR01AG058063 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI MARK W ALBERS, PETER Karl SORGER · 2018 to 2026
$7.8M
NIA NIH HHS R01 AG058063
6 · The paper itself

Abstract

Missing data, inaccuracies in medication lists, and recording delays in electronic health records (EHR) are major limitations for target trial emulation (TTE), which uses EHR data to retrospectively emulate a clinical trial. EHR-based TTE relies on recorded data that proxy actual drug exposures and outcomes. While prior work has proposed various methods to improve EHR data quality, here we investigate the underutilized consideration that encounters with a primary care provider (PCP) may result in more accurate data in the EHR. Patients with a PCP within the EHR network being studied tend to have more encounters overall and a greater proportion of the types of encounters that yield comprehensive and up-to-date records. By contrasting data for patients with and without a PCP in the considered EHR network, we demonstrate how PCP status affects EHR data quality. Through a case study, we then empirically examine the impact on TTE of including a PCP status feature either in the propensity score and outcome models or as an eligibility criterion for cohort selection, versus ignoring it. Specifically, we compare the estimated effects of two first-line antidiabetic drug classes on the onset of Alzheimer's Disease and Related Dementias. We find that the estimated treatment effect is sensitive to the consideration of PCP status, particularly when used as an eligibility criterion. Our work suggests that further researching the role of PCP status may improve the design of pragmatic trials.

Identifiers

PMID40297460
PMCPMC12036400

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.